ine metabolism with an ic50 of 62 micromolar, a concentration that is over 50 times higher than the cmax in healthy volunteers following 14 days of dosing with 20 mg of rabeprazole. this degree of inhibition is similar to that by omeprazole at equivalent concentrations. 7.4 compounds dependent on gastric ph for absorption due to its effects on gastric acid secretion, rabeprazole can reduce the absorption of drugs where gastric ph is an important determinant of their bioavailability. like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (mmf) can decrease, while the absorption of drugs such as digoxin can increase during treatment with rabeprazole sodium. concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the auc and cmax for digoxin by 19% and 29%, respectively. therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations. concomitant use of atazanavir and ppis is not recommended. co-administration of atazanavir with ppis is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect. co-administration of ppis in healthy subjects and in transplant patients receiving mmf has been reported to reduce the exposure to the active metabolite, mycophenolic acid (mpa), possibly due to a decrease in mmf solubility at an increased gastric ph. the clinical relevance of reduced mpa exposure on organ rejection has not been established in transplant patients receiving ppis and mmf. use rabeprazole sodium with caution in transplant patients receiving mmf. 7.5 drugs metabolized by cyp2c19 in a clinical study in japan evaluating rabeprazole in adult patients categorized by cyp2c19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. this could be due to higher rabeprazole plasma levels in poor metabolizers. whether or not interactions of rabeprazole sodium with other drugs metabolized by cyp2c19 would be different between extensive metabolizers and poor metabolizers has not been studied. 7.6 combined administration with clarithromycin combined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin [see clinical pharmacology (12.3)]. concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [see warnings and precautions in prescribing information for clarithromycin]. because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [see contraindications in prescribing information for clarithromycin] [see drug interactions in prescribing information for amoxicillin]. 7.7 methotrexate case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of ppis and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. however, no formal drug interaction studies of methotrexate with ppis have been conducted [see warnings and precautions (5.8)]. 7.8 clopidogrel concomitant administration of rabeprazole and clopidogrel in healthy subjects had no clinically meaningful effect on exposure to the active metabolite of clopidogrel [see clinical pharmacology (12.3)]. no dose adjustment of clopidogrel is necessary when administered with an approved dose of rabeprazole sodium.

l ulcers in adults rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. 1.5 helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence in adults rabeprazole sodium delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.5) and dosage and administration (2.5)]. in patients who fail therapy, susceptibility testing should be done. if resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see clinical pharmacology (12.2) and the clarithromycin package insert, clinical pharmacology (12.2)]. 1.6 treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome in adults rabeprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. 1.7 short-term treatment of symptomatic gerd in adolescent patients 12 years of age and older rabeprazole sodium delayed-release tablets are indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks.

stric body and 11% had atrophy in the gastric antrum. approximately 4% of patients had intestinal metaplasia at some point during follow-up, but no consistent changes were seen. 5.2 concomitant use with warfarin steady state interactions of rabeprazole and warfarin have not been adequately evaluated in patients. there have been reports of increased inr and prothrombin time in patients receiving a proton pump inhibitor and warfarin concomitantly. increases in inr and prothrombin time may lead to abnormal bleeding and even death. patients treated with a proton pump inhibitor and warfarin concomitantly may need to be monitored for increases in inr and prothrombin time. 5.3 acute interstitial nephritis acute interstitial nephritis has been observed in patients taking ppis including rabeprazole sodium. acute interstitial nephritis may occur at any point during ppi therapy and is generally attributed to an idiopathic hypersensitivity reaction. discontinue rabeprazole sodium if acute interstitial nephritis develops [see contraindications (4)]. 5.4 cyanocobalamin (vitamin b-12) deficiency daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin b-12) caused by hypo- or achlorhydria. rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. this diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed. 5.5 clostridium difficile associated diarrhea published observational studies suggest that ppi therapy like rabeprazole sodium may be associated with an increased risk of clostridium difficile associated diarrhea, especially in hospitalized patients. this diagnosis should be considered for diarrhea that does not improve [see adverse reaction (6.2)]. patients should use the lowest dose and shortest duration of ppi therapy appropriate to the condition being treated. clostridium difficile associated diarrhea (cdad) has been reported with use of nearly all antibacterial agents. for more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with rabeprazole sodium, refer to warnings and precautions sections of those package inserts. 5.6 bone fracture several published observational studies in adults suggest that ppi therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. the risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term ppi therapy (a year or longer). patients should use the lowest dose and shortest duration of ppi therapy appropriate to the condition being treated. patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see dosage and administration (2) and adverse reactions (6.2)]. 5.7 hypomagnesemia hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with ppis for at least three months, in most cases after a year of therapy. serious adverse events include tetany, arrhythmias, and seizures. in most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the ppi. for patients expected to be on prolonged treatment or who take ppis with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of ppi treatment and periodically [see adverse reactions (6.2)]. 5.8 concomitant use of rabeprazole sodium with methotrexate literature suggests that concomitant use of ppis with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. in high-dose methotrexate administration, a temporary withdrawal of the ppi may be considered in some patients [see drug interactions (7.7)].

mmended adult oral dose is one rabeprazole sodium 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks [see indications and usage (1.5)]. most patients with duodenal ulcer heal within four weeks. a few patients may require additional therapy to achieve healing. 2.5 helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence in adults table 1 three drug regimena all three medications should be taken twice daily with the morning and evening meals. ait is important that patients comply with the full 7-day regimen [see clinical studies (14.5)]. rabeprazole sodium delayed-release tablet 20 mg twice daily for 7 days amoxicillin 1000 mg twice daily for 7 days clarithromycin 500 mg twice daily for 7 days 2.6 treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome in adults the dosage of rabeprazole sodium delayed-release tablets in patients with pathologic hypersecretory conditions varies with the individual patient. the recommended adult oral starting dose is 60 mg once daily. doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. some patients may require divided doses. doses up to 100 mg qd and 60 mg bid have been administered. some patients with zollinger-ellison syndrome have been treated continuously with rabeprazole sodium delayed-release tablets for up to one year. 2.7 short-term treatment of symptomatic gerd in adolescent patients 12 years of age and older the recommended oral dose for adolescents 12 years of age and older is one 20 mg delayed-release tablet once daily for up to 8 weeks [see use in specific populations (8.4) and clinical studies (14.7)]. 2.9 elderly, renal, and hepatic impaired patients no dosage adjustment is necessary in elderly patients, in patients with renal disease, or in patients with mild to moderate hepatic impairment. administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients. 2.10 administration recommendations table 2 administration recommendations formulation population instructions delayed-release tablet adults and adolescents 12 years of age and older swallow tablets whole. do not chew, crush, or split tablets. tablets can be taken with or without food.

or 40 mg/day of rabeprazole sodium. an analysis of adverse reactions appearing in ≥2% of rabeprazole sodium patients (n=1064), and with a greater frequency than placebo (n=89) in controlled north american and european acute treatment trials, revealed the following adverse reactions: pain (3% vs. 1%), pharyngitis (3% vs. 2%), flatulence (3% vs. 1%), infection (2% vs. 1%), and constipation (2% vs. 1%). three long-term maintenance studies consisted of a total of 740 adult patients; at least 54% of adult patients were exposed to rabeprazole for 6 months and at least 33% were exposed for 12 months. of the 740 adult patients, 247 (33%) and 241 (33%) patients received 10 mg and 20 mg of rabeprazole sodium, respectively, while 169 (23%) patients received placebo and 83 (11%) received omeprazole. the safety profile of rabeprazole in the maintenance studies in adults was consistent with what was observed in the acute studies. other adverse reactions seen in controlled clinical trials, which do not meet the above criteria (≥2% of rabeprazole sodium-treated patients and greater than placebo) and for which there is a possibility of a causal relationship to rabeprazole, include the following: headache, abdominal pain, diarrhea, dry mouth, dizziness, peripheral edema, hepatic enzyme increase, hepatitis, hepatic encephalopathy, myalgia, and arthralgia. combination treatment with amoxicillin and clarithromycin: in clinical trials using combination therapy with rabeprazole plus amoxicillin and clarithromycin (rac), no adverse reactions unique to this drug combination were observed. in the u.s. multicenter study, the most frequently reported drug related adverse reactions for patients who received rac therapy for 7 or 10 days were diarrhea (8% and 7%) and taste perversion (6% and 10%), respectively. no clinically significant laboratory abnormalities particular to the drug combinations were observed. for more information on adverse reactions or laboratory changes with amoxicillin or clarithromycin, refer to their respective package prescribing information, adverse reactions section. pediatric in a multicenter, open-label study of adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic gerd or endoscopically proven gerd, the adverse event profile was similar to that of adults. the adverse reactions reported without regard to relationship to rabeprazole sodium that occurred in ≥2% of 111 patients were headache (9.9%), diarrhea (4.5%), nausea (4.5%), vomiting (3.6%), and abdominal pain (3.6%). the related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%). there were no adverse reactions reported in this study that were not previously observed in adults. 6.2 postmarketing experience the following adverse reactions have been identified during post approval use of rabeprazole sodium. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: sudden death; coma, hyperammonemia; jaundice; rhabdomyolysis; disorientation and delirium; anaphylaxis; angioedema; bullous and other drug eruptions of the skin; severe dermatologic reactions, including toxic epidermal necrolysis (some fatal), stevens-johnson syndrome, and erythema multiforme; interstitial pneumonia; interstitial nephritis; tsh elevations; bone fractures; hypomagnesemia and clostridium difficile associated diarrhea. in addition, agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, and thrombocytopenia have been reported. increases in prothrombin time/inr in patients treated with concomitant warfarin have been reported.

ine metabolism with an ic50 of 62 micromolar, a concentration that is over 50 times higher than the cmax in healthy volunteers following 14 days of dosing with 20 mg of rabeprazole. this degree of inhibition is similar to that by omeprazole at equivalent concentrations. 7.4 compounds dependent on gastric ph for absorption due to its effects on gastric acid secretion, rabeprazole can reduce the absorption of drugs where gastric ph is an important determinant of their bioavailability. like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (mmf) can decrease, while the absorption of drugs such as digoxin can increase during treatment with rabeprazole sodium. concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the auc and cmax for digoxin by 19% and 29%, respectively. therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations. concomitant use of atazanavir and ppis is not recommended. co-administration of atazanavir with ppis is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect. co-administration of ppis in healthy subjects and in transplant patients receiving mmf has been reported to reduce the exposure to the active metabolite, mycophenolic acid (mpa), possibly due to a decrease in mmf solubility at an increased gastric ph. the clinical relevance of reduced mpa exposure on organ rejection has not been established in transplant patients receiving ppis and mmf. use rabeprazole sodium with caution in transplant patients receiving mmf. 7.5 drugs metabolized by cyp2c19 in a clinical study in japan evaluating rabeprazole in adult patients categorized by cyp2c19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. this could be due to higher rabeprazole plasma levels in poor metabolizers. whether or not interactions of rabeprazole sodium with other drugs metabolized by cyp2c19 would be different between extensive metabolizers and poor metabolizers has not been studied. 7.6 combined administration with clarithromycin combined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin [see clinical pharmacology (12.3)]. concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [see warnings and precautions in prescribing information for clarithromycin]. because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [see contraindications in prescribing information for clarithromycin] [see drug interactions in prescribing information for amoxicillin]. 7.7 methotrexate case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of ppis and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. however, no formal drug interaction studies of methotrexate with ppis have been conducted [see warnings and precautions (5.8)]. 7.8 clopidogrel concomitant administration of rabeprazole and clopidogrel in healthy subjects had no clinically meaningful effect on exposure to the active metabolite of clopidogrel [see clinical pharmacology (12.3)]. no dose adjustment of clopidogrel is necessary when administered with an approved dose of rabeprazole sodium.

es the human exposure at the recommended oral dose for gerd) and have revealed no evidence of harm to the fetus due to rabeprazole. administration of rabeprazole to rats in late gestation and during lactation at an oral dose of 400 mg/kg/day (about 195 times the human oral dose based on mg/m2) resulted in decreases in body weight gain of the pups. a pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development was performed with a different ppi at about 3.4 to 57 times an oral human dose on a body surface area basis. decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate, and minimal to mild bone marrow hypocellularity were noted at doses of this ppi equal to or greater than 3.4 times an oral human dose on a body surface area basis. physeal dysplasia in the femur was also observed in offspring after in utero and lactational exposure to the ppi at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis. effects on maternal bone were observed in pregnant and lactating rats in a pre- and postnatal toxicity study when the ppi was administered at oral doses of 3.4 to 57 times an oral human dose on a body surface area basis. when rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis. 8.3 nursing mothers it is not known if rabeprazole sodium is excreted in human milk; however, rabeprazole is present in rat milk. because many drugs are excreted in milk, caution should be exercised when rabeprazole sodium is administered to a nursing woman. 8.4 pediatric use symptomatic gerd in adolescent patients greater or equal to 12 years of age in a multicenter, randomized, open-label, parallel-group study, 111 adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic gerd, or suspected or endoscopically proven gerd, were randomized and treated with either rabeprazole sodium 10 mg or rabeprazole sodium 20 mg once daily for up to 8 weeks for the evaluation of safety and efficacy. the adverse event profile in adolescent patients was similar to that of adults. the related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%). there were no adverse reactions reported in these studies that were not previously observed in adults. 8.5 geriatric use of the total number of subjects in clinical studies of rabeprazole sodium, 19% were 65 years and over, while 4% were 75 years and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 8.6 gender duodenal ulcer and erosive esophagitis healing rates in women are similar to those in men. adverse reactions and laboratory test abnormalities in women occurred at rates similar to those in men.

ole sodium. the median inhibitory effect of rabeprazole sodium on 24-hour gastric acidity is 88% of maximal after the first dose. rabeprazole sodium 20 mg inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively, and increases the percent of a 24-hour period that the gastric ph>3 from 10% to 65% (see table below). this relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the h+, k+atpase. table 3 gastric acid parameters rabeprazole sodium versus placebo after 7 days of once daily dosing *(p<0.01 versus placebo) parameter rabeprazole sodium (20 mg qd) placebo basal acid output 0.4* 2.8 (mmol/hr) stimulated acid output 0.6* 13.3 (mmol/hr) % time gastric ph>3 65* 10 compared to placebo, rabeprazole sodium, 10 mg, 20 mg, and 40 mg, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. in this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity. the ability of rabeprazole to cause a dose-related decrease in mean intragastric acidity is illustrated below. table 4 auc acidity (mmol•hr/l) rabeprazole sodium versus placebo on day 7 of once daily dosing (mean±sd) *(p<0.001 versus placebo) treatment auc 10 mg 20 mg 40 mg placebo interval rbp rbp rbp (n=24) (hrs) (n=24) (n=24) (n=24) 08:00 to 13:00 19.6±21.5* 12.9±23* 7.6±14.7* 91.1±39.7 13:00 to 19:00 5.6±9.7* 8.3±29.8* 1.3±5.2* 95.5±48.7 19:00 to 22:00 0.1±0.1* 0.1±0.06* 0.0±0.02* 11.9±12.5 22:00 to 08:00 129.2±84* 109.6±67.2* 76.9±58.4* 479.9±165 auc 0 to 24 hours 155.5±90.6* 130.9±81* 85.8±64.3* 678.5±216 after administration of 20 mg rabeprazole sodium tablets once daily for eight days, the mean percent of time that gastric ph>3 or gastric ph>4 after a single dose (day 1) and multiple doses (day 8) was significantly greater than placebo (see table below). the decrease in gastric acidity and the increase in gastric ph observed with 20 mg rabeprazole sodium tablets administered once daily for eight days were compared to the same parameters for placebo, as illustrated below: table 5 gastric acid parameters rabeprazole sodium once daily dosing versus placebo on day 1 and day 8 ano inferential statistics conducted for this parameter. *(p<0.001 versus placebo) bgastric ph was measured every hour over a 24-hour period. parameter rabeprazole sodium 20 mg qd placebo day 1 day 8 day 1 day 8 mean auc0 to 24 acidity 340.8* 176.9* 925.5 862.4 median trough ph (23-hr)a 3.77 3.51 1.27 1.38 % time gastric ph>3b 54.6* 68.7* 19.1 21.7 % time gastric ph>4b 44.1* 60.3* 7.6 11.0 effects on esophageal acid exposure in patients with gastroesophageal reflux disease (gerd) and moderate to severe esophageal acid exposure, rabeprazole sodium 20 mg and 40 mg tablets per day decreased 24-hour esophageal acid exposure. after seven days of treatment, the percentage of time that esophageal ph<4 decreased from baselines of 24.7% for 20 mg and 23.7% for 40 mg, to 5.1% and 2.0%, respectively. normalization of 24-hour intraesophageal acid exposure was correlated to gastric ph>4 for at least 35% of the 24-hour period; this level was achieved in 90% of subjects receiving rabeprazole sodium 20 mg and in 100% of subjects receiving rabeprazole sodium 40 mg. with rabeprazole sodium 20 mg and 40 mg per day, significant effects on gastric and esophageal ph were noted after one day of treatment, and more pronounced after seven days of treatment. effects on serum gastrin in patients given daily doses of rabeprazole sodium for up to eight weeks to treat ulcerative or erosive esophagitis and in patients treated for up to 52 weeks to prevent recurrence of disease, the median fasting gastrin level increased in a dose-related manner. the group median values stayed within the normal range. in a group of subjects treated daily with rabeprazole sodium 20 mg tablets for 4 weeks, a doubling of mean serum gastrin concentrations was observed. approximately 35% of these treated subjects developed serum gastrin concentrations above the upper limit of normal. in a study of cyp2c19 genotyped subjects in japan, poor metabolizers developed statistically significantly higher serum gastrin concentrations than extensive metabolizers. effects on enterochromaffin-like (ecl) cells increased serum gastrin secondary to antisecretory agents stimulates proliferation of gastric ecl cells, which, over time, may result in ecl cell hyperplasia in rats and mice and gastric carcinoids in rats, especially in females [see nonclinical toxicology (13.1)]. in over 400 patients treated with rabeprazole sodium tablets (10 or 20 mg/day) for up to one year, the incidence of ecl cell hyperplasia increased with time and dose, which is consistent with the pharmacological action of the proton-pump inhibitor. no patient developed the adenomatoid, dysplastic, or neoplastic changes of ecl cells in the gastric mucosa. no patient developed the carcinoid tumors observed in rats. endocrine effects studies in humans for up to one year have not revealed clinically significant effects on the endocrine system. in healthy male volunteers treated with rabeprazole sodium for 13 days, no clinically relevant changes have been detected in the following endocrine parameters examined: 17 β-estradiol, thyroid stimulating hormone, tri-iodothyronine, thyroxine, thyroxine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteotrophic hormone, prolactin, somatotrophic hormone, dehydroepiandrosterone, cortisol-binding globulin, and urinary 6β-hydroxycortisol, serum testosterone and circadian cortisol profile. other effects in humans treated with rabeprazole sodium for up to one year, no systemic effects have been observed on the central nervous, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems. no data are available on long-term treatment with rabeprazole sodium and ocular effects. microbiology the following in vitro data are available but the clinical significance is unknown. rabeprazole sodium, amoxicillin, and clarithromycin as a three drug regimen has been shown to be active against most strains of helicobacter pylori in vitro and in clinical infections as described in the clinical studies (14) and indications and usage (1) sections. helicobacter pylori susceptibility testing of h. pylori isolates was performed for amoxicillin and clarithromycin using agar dilution methodology1, and minimum inhibitory concentrations (mics) were determined. standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. incidence of antibiotic-resistant organisms among clinical isolates pretreatment resistance: clarithromycin pretreatment resistance rate (mic ≥1 mcg/ml) to h. pylori was 9% (51/560) at baseline in all treatment groups combined. a total of >99% (558/560) of patients had h. pylori isolates, which were considered to be susceptible (mic ≤0.25 mcg/ml) to amoxicillin at baseline. two patients had baseline h. pylori isolates with an amoxicillin mic of 0.5 mcg/ml. for susceptibility testing information about helicobacter pylori, see microbiology section in prescribing information for clarithromycin and amoxicillin. table 6 clarithromycin susceptibility test results and clinical/bacteriologic outcomesafor a three drug regimen (rabeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 7 or 10 days) aincludes only patients with pretreatment and post-treatment clarithromycin susceptibility test results. b susceptible (s) mic ≤ 0.25 mcg /ml, intermediate (i) mic = 0.5 mcg/ml, resistant (r) mic ≥ 1 mcg/ml days of rac therapy clarithromycin pretreatment results total number h. pylori negative (eradicated) h. pylori positive (persistent) post-treatment susceptibility results s b i b r b no mic 7 susceptible b 129 103 2 0 1 23 7 intermediate b 0 0 0 0 0 0 7 resistant b 16 5 2 1 4 4 10 susceptible b 133 111 3 1 2 16 10 intermediate b 0 0 0 0 0 0 10 resistant b 9 1 0 0 5 3 patients with persistent h. pylori infection following rabeprazole, amoxicillin, and clarithromycin therapy will likely have clarithromycin resistant clinical isolates. therefore, clarithromycin susceptibility testing should be done when possible. if resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted. amoxicillin susceptibility test results and clinical/bacteriological outcomes: in the u.s. multicenter study, a total of >99% (558/560) of patients had h. pylori isolates which were considered to be susceptible (mic ≤ 0.25 mcg/ml) to amoxicillin at baseline. the other two patients had baseline h. pylori isolates with an amoxicillin mic of 0.5 mcg/ml, and both isolates were clarithromycin-resistant at baseline; in one case the h. pylori was eradicated. in the 7- and 10-day treatment groups, 75% (107/145) and 79% (112/142), respectively, of the patients who had pretreatment amoxicillin susceptible mics (≤ 0.25 mcg/ml) were eradicated of h. pylori. no patients developed amoxicillin-resistant h. pylori during therapy. 12.3 pharmacokinetics rabeprazole sodium delayed-release tablets are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through the stomach relatively intact. after oral administration of 20 mg rabeprazole sodium tablet, peak plasma concentrations (cmax) of rabeprazole occur over a range of 2.0 to 5.0 hours (tmax). the rabeprazole cmax and auc are linear over an oral dose range of 10 mg to 40 mg. there is no appreciable accumulation when doses of 10 mg to 40 mg are administered every 24 hours; the pharmacokinetics of rabeprazole is not altered by multiple dosing. absorption: absolute bioavailability for a 20 mg oral tablet of rabeprazole (compared to intravenous administration) is approximately 52%. when rabeprazole sodium tablets are administered with a high fat meal, tmax is variable, which concomitant food intake may delay the absorption up to 4 hours or longer. however, the cmax and the extent of rabeprazole absorption (auc) are not significantly altered. thus rabeprazole sodium tablets may be taken without regard to timing of meals. distribution: rabeprazole is 96.3% bound to human plasma proteins. metabolism: rabeprazole is extensively metabolized. a significant portion of rabeprazole is metabolized via systemic nonenzymatic reduction to a thioether compound. rabeprazole is also metabolized to sulphone and desmethyl compounds via cytochrome p450 in the liver. the thioether and sulphone are the primary metabolites measured in human plasma. these metabolites were not observed to have significant antisecretory activity. in vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes p450 3a (cyp3a) to a sulphone metabolite and cytochrome p450 2c19 (cyp2c19) to desmethyl rabeprazole. cyp2c19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g. 3 to 5% of caucasians and 17 to 20% of asians). rabeprazole metabolism is slow in these sub-populations, therefore, they are referred to as poor metabolizers of the drug. elimination: following a single 20 mg oral dose of 14c-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid, its glucuronide, and mercapturic acid metabolites. the remainder of the dose was recovered in the feces. total recovery of radioactivity was 99.8%. no unchanged rabeprazole was recovered in the urine or feces. geriatric: in 20 healthy elderly subjects administered 20 mg rabeprazole tablet once daily for seven days, auc values approximately doubled and the cmax increased by 60% compared to values in a parallel younger control group. there was no evidence of drug accumulation after once daily administration [see use in specific population (8.5)]. pediatric: the pharmacokinetics of rabeprazole was studied in pediatric patients with gerd aged 12 to 16 years. patients 12 to 16 years of age the pharmacokinetics of rabeprazole was studied in 12 adolescent patients with gerd 12 to 16 years of age, in a multicenter study. patients received rabeprazole 20 mg tablets once daily for five or seven days. an approximate 40% increase in exposure was noted following 5 to 7 days of dosing compared with the exposure after 1 day dosing. pharmacokinetic parameters in adolescent patients with gerd 12 to 16 years of age were within the range observed in healthy adult volunteers. gender and race: in analyses adjusted for body mass and height, rabeprazole pharmacokinetics showed no clinically significant differences between male and female subjects. in studies that used different formulations of rabeprazole, auc0-∞ values for healthy japanese men were approximately 50 to 60% greater than values derived from pooled data from healthy men in the united states. renal disease: in 10 patients with stable end-stage renal disease requiring maintenance hemodialysis (creatinine clearance ≤5 ml/min/1.73 m2), no clinically significant differences were observed in the pharmacokinetics of rabeprazole after a single 20 mg oral dose when compared to 10 healthy volunteers [see dosage and administration (2.9)]. hepatic disease: in a single dose study of 10 patients with chronic mild to moderate compensated cirrhosis of the liver who were administered a 20 mg dose of rabeprazole, auc0 to 24 was approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance was decreased to less than half compared to values in healthy men. in a multiple dose study of 12 patients with mild to moderate hepatic impairment administered 20 mg rabeprazole once daily for eight days, auc0-∞ and cmax values increased approximately 20% compared to values in healthy age- and gender-matched subjects. these increases were not statistically significant. no information exists on rabeprazole disposition in patients with severe hepatic impairment. please refer to the dosage and administration (2.9) for information on dosage adjustment in patients with hepatic impairment. combined administration with antimicrobials: sixteen healthy volunteers genotyped as extensive metabolizers with respect to cyp2c19 were given 20 mg rabeprazole sodium, 1000 mg amoxicillin, 500 mg clarithromycin, or all 3 drugs in a four-way crossover study. each of the four regimens was administered twice daily for 6 days. the auc and cmax for clarithromycin and amoxicillin were not different following combined administration compared to values following single administration. however, the rabeprazole auc and cmax increased by 11% and 34%, respectively, following combined administration. the auc and cmax for 14-hydroxyclarithromycin (active metabolite of clarithromycin) also increased by 42% and 46%, respectively. this increase in exposure to rabeprazole and 14-hydroxyclarithromycin is not expected to produce safety concerns. concomitant use with clopidogrel: clopidogrel is metabolized to its active metabolite in part by cyp2c19. a study of healthy subjects, including cyp2c19 extensive and intermediate metabolizers receiving once daily administration of clopidogrel 75 mg concomitantly with placebo or with rabeprazole sodium 20 mg (n=36), for 7 days was conducted. the mean auc of the active metabolite of clopidogrel was reduced by approximately 12% (mean auc ratio was 88%, with 90% ci of 81.7% to 95.5%) when rabeprazole sodium was coadministered compared to administration of clopidogrel with placebo.

terochromaffin-like (ecl) cell hyperplasia in male and female rats and ecl cell carcinoid tumors in female rats at all doses including the lowest tested dose. the lowest dose (5 mg/kg/day) produced a systemic exposure to rabeprazole (auc) of about 0.1 mcg•hr/ml, which is about 0.1 times the human exposure at the recommended dose for gerd. in male rats, no treatment related tumors were observed at doses up to 60 mg/kg/day producing a rabeprazole plasma exposure (auc) of about 0.2 mcg•hr/ml (0.2 times the human exposure at the recommended dose for gerd). rabeprazole was positive in the ames test, the chinese hamster ovary cell (cho/hgprt) forward gene mutation test, and the mouse lymphoma cell (l5178y/tk+/–) forward gene mutation test. its demethylated-metabolite was also positive in the ames test. rabeprazole was negative in the in vitro chinese hamster lung cell chromosome aberration test, the in vivo mouse micronucleus test, and the in vivo and ex vivo rat hepatocyte unscheduled dna synthesis (uds) tests. rabeprazole at intravenous doses up to 30 mg/kg/day (plasma auc of 8.8 mcg•hr/ml, about 10 times the human exposure at the recommended dose for gerd) was found to have no effect on fertility and reproductive performance of male and female rats. 13.2 animal toxicology and/or pharmacology studies in juvenile and young adult rats and dogs were performed. in juvenile animal studies rabeprazole sodium was administered orally to rats for up to 5 weeks and to dogs for up to 13 weeks, each commencing on day 7 post-partum and followed by a 13-week recovery period. rats were dosed at 5, 25, or 150 mg/kg/day and dogs were dosed at 3, 10, or 30 mg/kg/day. the data from these studies were comparable to those reported for young adult animals. pharmacologically mediated changes, including increased serum gastrin levels and stomach changes, were observed at all dose levels in both rats and dogs. these observations were reversible over the 13-week recovery periods. although body weights and/or crown-rump lengths were minimally decreased during dosing, no effects on the development parameters were noted in either juvenile rats or dogs. when juvenile animals were treated for 28 days with a different ppi at doses equal to or greater than 34 times the daily oral human dose on a body surface area basis, overall growth was affected and treatment-related decreases in body weight (approximately 14%) and body weight gain, and decreases in femur weight and femur length were observed.

ficant difference in favor of the rabeprazole sodium 10 mg, 20 mg, and 40 mg doses compared to placebo at weeks 4 and 8 regarding complete resolution of gerd heartburn frequency (p≤0.026). all rabeprazole sodium groups reported significantly greater rates of complete resolution of gerd daytime heartburn severity compared to placebo at weeks 4 and 8 (p≤0.036). mean reductions from baseline in daily antacid dose were statistically significant for all rabeprazole sodium groups when compared to placebo at both weeks 4 and 8 (p≤0.007). in a north american multicenter, randomized, double-blind, active-controlled study of 336 patients, rabeprazole sodium was statistically superior to ranitidine with respect to the percentage of patients healed at endoscopy after four and eight weeks of treatment (see table below): table 8 healing of erosive or ulcerativegastroesophageal reflux disease (gerd) percentage of patients healed *(p<0.001 versus ranitidine) week rabeprazole sodium 20 mg qd n=167 ranitidine 150 mg qid n=169 4 59%* 36% 8 87%* 66% rabeprazole sodium 20 mg once daily was significantly more effective than ranitidine 150 mg qid in the percentage of patients with complete resolution of heartburn at weeks 4 and 8 (p<0.001). rabeprazole sodium 20 mg once daily was also more effective in complete resolution of daytime heartburn (p≤0.025), and nighttime heartburn (p≤0.012) at both weeks 4 and 8, with significant differences by the end of the first week of the study. 14.2 long-term maintenance of healing of erosive or ulcerative gerd in adults the long-term maintenance of healing in patients with erosive or ulcerative gerd previously healed with gastric antisecretory therapy was assessed in two u.s. multicenter, randomized, double-blind, placebo-controlled studies of identical design of 52 weeks duration. the two studies randomized 209 and 285 patients, respectively, to receive either 10 mg or 20 mg of rabeprazole sodium qd or placebo. as demonstrated in the tables below, rabeprazole sodium was significantly superior to placebo in both studies with respect to the maintenance of healing of gerd and the proportions of patients remaining free of heartburn symptoms at 52 weeks: table 9 percent of patients in endoscopic remission *(p(0.001 versus placebo) rabeprazole sodium 10 mg rabeprazole sodium 20 mg placebo study 1 n=66 n=67 n=70 week 4 83%* 96%* 44% week 13 79%* 93%* 39% week 26 77%* 93%* 31% week 39 76%* 91%* 30% week 52 73%* 90%* 29% study 2 n=93 n=93 n=99 week 4 89%* 94%* 40% week 13 86%* 91%* 33% week 26 85%* 89%* 30% week 39 84%* 88%* 29% week 52 77%* 86%* 29% combined studies n=159 n=160 n=169 week 4 87%* 94%* 42% week 13 83%* 92%* 36% week 26 82%* 91%* 31% week 39 81%* 89%* 30% week 52 75%* 87%* 29% table 10 percent of patients without relapse in heartburnfrequency and daytime and nighttime heartburnseverity at week 52 *p≤0.001 versus placebo † 0.001

How Supplied:

Rabeprazole sodium 20 mg is supplied as yellow colored, round, biconvex delayed-release tablets imprinted with '107' on one side in black ink and plain on other side. store at 20° to 25°c (68° to 77°f), excursions permitted to 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. protect from moisture.

Package Label Principal Display Panel:

225